<DOC>
	<DOCNO>NCT01193101</DOCNO>
	<brief_summary>This study phase 2 study patient essential hypertension .</brief_summary>
	<brief_title>Efficacy Safety LCZ696 Compared Placebo Patients With Essential Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>1 . Patients must give write informed consent assessment perform . 2 . Patients mild moderate essential hypertension , untreated currently take antihypertensive therapy ( mean sit diastolic blood pressure ≥ 95 mmHg &lt; 110 mmHg , mean sit systolic blood pressure ≥ 140 mmHg &lt; 180 mmHg ) . 3 . Patients must willing able undergo ambulatory blood pressure monitor 24hr period begin end 8week treatment . 4 . Patient must able communicate comply study requirement demonstrate good medication compliance . 1 . Patients severe hypertension . 2 . Patients history angioedema , drugrelated otherwise 3 . Pregnant nursing woman 4 . Women childbearing potential , use adequate birth control methods 5 . History evidence secondary form hypertension . 6 . History angina pectoris , myocardial infarction , coronary bypass surgery , ischemic heart disease , surgical percutaneous arterial intervention kind , stroke , TIA , carotid artery stenosis , aortic aneurysm , peripheral arterial disease . 7 . Diabetes mellitus . 8 . Previous current diagnosis heart failure ( NYHA Class IIIV ) . 9 . Clinically significant valvular heart disease time screen . Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>hypertension</keyword>
	<keyword>blood pressure</keyword>
	<keyword>LCZ696</keyword>
	<keyword>dual-acting</keyword>
	<keyword>neprilysin</keyword>
	<keyword>nep inhibitor</keyword>
	<keyword>vasopeptidase</keyword>
	<keyword>angiotensin receptor</keyword>
	<keyword>ARNi</keyword>
	<keyword>Essential hypertension</keyword>
</DOC>